Over 70% of metastatic breast cancers are hormone receptor-positive (HR+) and are treated with sequential endocrine-based therapies.1–4 Endocrine therapies (ETs) may initially be efficacious and well-tolerated in a substantial proportion of patients with HR+ breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.